Amedisys Management

Management criteria checks 1/4

Amedisys' CEO is Richard Ashworth, appointed in Apr 2023, has a tenure of less than a year. directly owns 0.34% of the company’s shares, worth $10.38M. The average tenure of the management team and the board of directors is 1.5 years and 4.3 years respectively.

Key information

Richard Ashworth

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.3%
Management average tenure1.5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Apr 14
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

CEO

Richard Ashworth (48 yo)

less than a year

Tenure

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...


Leadership Team

NamePositionTenureCompensationOwnership
Scott Ginn
Executive VP6.4yrsUS$4.16m0.067%
$ 2.0m
Michael North
Chief Information Officer7.3yrsUS$1.19m0.033%
$ 981.4k
Denise Bohnert
Chief Compliance Officer4.5yrsUS$899.96kno data
Nick Muscato
Chief Strategy Officerno dataUS$1.90m0.0061%
$ 183.3k
Richard Ashworth
Presidentless than a yearno data0.34%
$ 10.4m
Allyson Guidroz
Chief Accounting Officer & Principal Accounting Officerless than a yearno data0.0096%
$ 289.3k
Pete Hartley
CTO & Senior VP of Business Operations Systemsno datano datano data
Jennifer Griffin
Senior VP1.4yrsno datano data
Kendra Kimmons
VP of Marketing & Communications & Media Relationsno datano datano data
Adam Holton
Chief People Officer1.5yrsno data0.00029%
$ 8.7k
Francis Mayer
Senior Vice President of Developmentno datano datano data

1.5yrs

Average Tenure

50yo

Average Age

Experienced Management: AMED's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Richard Ashworth
Presidentless than a yearno data0.34%
$ 10.4m
Paul Kusserow
Chairman9.3yrsUS$4.08m1.34%
$ 40.2m
Bruce Perkins
Independent Director8.9yrsUS$265.04k0.054%
$ 1.6m
Vickie Capps
Independent Director4.3yrsUS$275.04k0.0098%
$ 295.3k
Molly Coye
Independent Director4.3yrsUS$261.29k0.0067%
$ 203.2k
Julie Klapstein
Lead Independent DIrector7.9yrsUS$277.54k0.029%
$ 867.9k
Jeffrey Rideout
Independent Director7.9yrsUS$265.04k0.0083%
$ 250.8k
Teresa Kline
Independent Director4.3yrsUS$265.04k0.0098%
$ 295.3k
Ivanetta Samuels
Independent Director3.3yrsUS$250.04k0.0030%
$ 90.9k

4.3yrs

Average Tenure

62yo

Average Age

Experienced Board: AMED's board of directors are considered experienced (4.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.